diflomotecan has been researched along with quinazolines in 1 studies
| Studies (diflomotecan) | Trials (diflomotecan) | Recent Studies (post-2010) (diflomotecan) | Studies (quinazolines) | Trials (quinazolines) | Recent Studies (post-2010) (quinazolines) |
|---|---|---|---|---|---|
| 17 | 4 | 3 | 19,235 | 2,417 | 8,835 |
| Protein | Taxonomy | diflomotecan (IC50) | quinazolines (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.027 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maneely, D | 1 |
1 other study(ies) available for diflomotecan and quinazolines
| Article | Year |
|---|---|
Clinical Trials in Cancer-SMi Conference. 11-12 June 2003, London, UK.
Topics: Antineoplastic Agents; Camptothecin; Cancer Vaccines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Erlotinib Hydrochloride; Humans; Molecular Structure; Neoplasms; Quinazolines; Treatment Outcome | 2003 |